Puff Puff Post

MARCH 10, 2020

” Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period as part of a randomized, vehicle controlled, double-blind, Phase 1 trial. Visit [link].

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

OCTOBER 6, 2021

(NASDAQ: FLGC) (“Flora” or the “Company”), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, is pleased to announce that it has signed an agreement to begin scientific clinical trials globally. or follow @floragrowthcorp on social for more information. Visit www.floragrowth.ca

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

MMJ Recs

APRIL 1, 2024

We’re exploring the world of CBD, uncovering the benefits of CBD in medical marijuana, its impact on health, its potential as a treatment option, and what you need to know about its use in medical marijuana. CBD: A Promising Treatment Option One of the most compelling aspects of CBD is its versatility as a treatment option.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

MMJ Recs

MAY 9, 2024

In this instance, medical cannabis offers a promising alternative or complementary treatment option. For veterans considering medical marijuana as a treatment option, it’s essential to approach its usage with careful consideration and understanding. Image by National Cancer Institute on Unsplash.

Research and Development 52

Research and Development Therapy Clinical Trials Treatment 52

Veriheal

JUNE 30, 2023

For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial. The 13 individuals were chosen because of their reported improvements in negative drinking behavior following the clinical trial.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Cannabis Law Report

DECEMBER 7, 2021

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. The search included studies through 11-May-2020. Introduction. Search strategy.

Safety 52

Safety Cannabinoids Events Data 52

Cannabis Law Report

AUGUST 17, 2021

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

JUNE 21, 2021

In the medical cannabis industry, mostly due to the plant’s long history of prohibition, there is a decided lack of data regarding the use and efficacy of cannabis as a treatment for a wide variety of indications. Over the prior three years or so, 41,260 RYAH-connected patients reported medical cannabis use for the treatment of pain.

Data 105

Data Clinical Trials Research and Development Indica 105

Cannabis Law Report

NOVEMBER 19, 2021

“These additional patent filings are key as PsyBio moves towards the initiation of appropriately approved safety and efficacy clinical trials for our selected compounds within the production and manufacturing arena, for the Company as well as for our investors.”

Clinical Trials 52

Clinical Trials Research and Development Events Safety 52

Canna Care Docs

OCTOBER 3, 2023

As a devastating diagnosis, patients with a terminal illness must not only learn to cope with this information about their health but find restorative ways to alleviate the most common symptoms and effects. One study from the Journal of Clinical Oncology examined the efficacy of cannabinoids in appetite stimulation.

Chronic Pain 105

Chronic Pain Clinical Trials Patients Cannabinoids 105

Cannabis Law Report

AUGUST 3, 2021

Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. Cybin makes no medical, treatment or health benefit claims about Cybin’s proposed products.

Clinical Trials 105

Clinical Trials Events Treatment Banking 105

Medicinal Marijuana Association

FEBRUARY 11, 2024

The potential link between cannabis and glaucoma treatment is a topic of ongoing investigation, stirring both curiosity and caution within the medical community. Potential for enhanced treatment outcomes with cannabis use. Improves optic nerve blood flow and protects retinal cells.

Treatment 52

Treatment Blood Pressure Conditions Clinical Trials 52

Cannabis Law Report

JULY 24, 2021

The groundbreaking progress that we’ve seen from the Multidisciplinary Association for Psychedelic Studies (MAPS) in its Phase 3 clinical trials of MDMA-assisted psychotherapy for Post-Traumatic Stress Disorder (PTSD), including receiving Breakthrough Therapy Designation from the Food and Drug Administration (FDA), shows great promise to date.

Research and Development 105

Research and Development Clinical Trials Therapy Events 105

The Cannigma

FEBRUARY 2, 2021

In light of these results, the researchers behind the survey say that physicians should pay special consideration to these aspects when advising patients on their medical cannabis treatment options. Physicians should consider these aspects when advising their patients about treatment with medicinal cannabis. Still, research is ongoing.

Patients 87

Patients Clinical Trials Research and Development Treatment 87

Cannabis Law Report

AUGUST 5, 2021

Psychedelics are quickly emerging as alternative methods of treatment for mental illnesses and neurodegenerative conditions — particularly in countries such as Canada. For more information, visit filament.health. Over the next several years, the psychedelics industry is expected to grow at a compound annual growth rate of 16.3

Extraction 105

Extraction Clinical Trials Research and Development Pharmaceutical 105

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

The Cannigma

MARCH 7, 2022

What can the current clinical trials tell us? A common theme with cannabis is that more research is needed, so thankfully there are clinical trials in the works looking at the therapeutic utility of CBN. Those enrolled in the study will receive 28 days of treatment and then be assessed by pain-rating scales.

THC 140

THC Sleep Clinical Trials Cannabinoids 140

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. This is the largest trial ever conducted in psilocybin therapy, and it was done amid the lockdowns and challenges of the COVID pandemic. million, or $0.79 million, or $2.61

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Cannabis Law Report

OCTOBER 13, 2021

The PCT filing also includes support for future research programs respecting various systems which seek to minimize negative side effects in psychedelic psychotherapy patients, methods that enable lower and sub-psychedelic doses without impacting treatment efficacy and increasing the long-term efficacy of psychedelic sessions. About Cybin.

Clinical Trials 52

Clinical Trials Research and Development Treatment Conditions 52

PrestoDoctor

OCTOBER 11, 2023

However, as part of a comprehensive treatment plan, CBD may offer a complementary approach to address some of the social symptoms associated with ASD. Another study involving human participants reported a significant reduction in anxiety and improvement in social communication skills after CBD treatment.

CBD 52

CBD Research and Development Clinical Trials Treatment 52

Cannabis Law Report

SEPTEMBER 22, 2021

This change would mean it would be easier to run trials on its use in mental health treatments. The Prime Minister had already approved the rescheduling of psilocybin for exploring its potential as a treatment for depression, which he informed Mr Blunt in a meeting in May.

Research and Development 52

Research and Development Clinical Trials Treatment History 52

Cannabis Law Report

JANUARY 12, 2022

This level of understanding can inform best practices, improve outcomes, and contribute to sensible policy-making both in Oregon and beyond. Through this collaboration, the NPA and Maya will offer both the education and the technology infrastructure needed to make this possible, ensuring accessibility and safety to all communities. “We

Research and Development 52

Research and Development Therapy Safety Clinical Trials 52

Cannabis Law Report

JUNE 4, 2021

– Drug Demonstrates Efficacy and Safety in Advanced Prostate Cancer Patients. – Phase 2 Trial Underway. Additionally, this novel antibody conjugate demonstrated very good tolerability during this DLT phase 1 trial. Clinical trial information: NCT03276572 ( [link] ). Abstract Number: 5015.

Data 100

Data Research and Development Clinical Trials Therapy 100

Cannabis Law Report

NOVEMBER 22, 2019

MMJ will be utilizing its new products for an FDA approved treatment of multiple sclerosis (MS) and Huntington’s disease (HD). for its THC and CBD proprietary drug formulation which will be used for the treatment of Huntington’s Disease. For more information visit: [link]. Orphan Drug Designation? 561-627-9455.

DEA 66

DEA Clinical Trials THC Research and Development 66

Cannabis Law Report

DECEMBER 26, 2021

The patent relates to improved technology for detection and maintenance of the optimal therapeutic psychedelic state, which Entheon intends to study through the monitoring of electroencephalogram (EEG) biomarkers in order to optimize the treatment of neuropsychiatric conditions. US Provisional Patent Filed. About Entheon Biomedical Corp.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

Otherside Farms

JANUARY 25, 2019

“This meta-analysis of pre-clinical stroke studies provides valuable information on the existing, and importantly, missing data on the use of cannabinoids as a potential treatment for stroke patients. The findings have identified the potential for cannabinoids to reduce brain damage caused by stroke.

Clinical Trials 74

Clinical Trials Marijuana Cannabinoids Data 74

Cannabis Law Report

JULY 29, 2021

Tetra Bio-Pharma ( TSX: TBP ) ( OTCQB: TBPMF ) ( FRA:JAM1 ) is a leader in cannabinoid-derived drug discovery and development with a FDA and a Health Canada cleared clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. For more information visit: www.tetrabiopharma.com.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Cannabis Law Report

DECEMBER 5, 2021

MAPS is currently sponsoring the final of two FDA-required Phase 3 trials of MDMA-assisted therapy for PTSD following the successful completion of the first Phase 3 trial and peer-reviewed publication of results in Nature Medicine earlier this year. Interested prospective funders can submit their contact information here.

Therapy 52

Therapy Access Research and Development Clinical Trials 52

Cannabis Law Report

JULY 14, 2021

(“ImmunoFlex” ), today announced that it has completed and analyzed its clinical trial of 21 patients, aged 60 to 70 years. For more information, visit www.Chemistree.ca. Additional studies in this area are ongoing,” said ImmunoFlex CEO Chris Wagner. federal law. Enforcement of U.S.

Research and Development 105

Research and Development Clinical Trials Events Treatment 105

Cannabis Law Report

JULY 1, 2021

Clinical trials repeatedly demonstrate their promise for treating mood, anxiety, and substance use disorders. In 2017, the FDA designated MDMA a breakthrough therapy for post-traumatic stress disorder, and in 2018 the agency identified psilocybin as a breakthrough for treatment-resistant depression. The Project. Watson, Jr.

Law 59

Law Policy Research and Development Clinical Trials 59

Cannabis Law Report

NOVEMBER 16, 2021

Our treatment designed for delaying aging has a distinctive drug profile of oral delivery, selectivity, and very low toxicity as compared with TNF blockers, all of which are delivered by injection only. The secondary measures will be the safety, tolerability, and pharmacokinetics in this population of patients. Chapman continued.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

FEBRUARY 28, 2022

Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. 1025, 1026 (2021) (reporting significant improvement of PTSD symptoms following treatment with MDMA in clinical trial); see also Alec J. Mitchell et al., Divito & Robert F. TIMES (Nov.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

Cannabis Law Report

MAY 29, 2022

Widespread approval for psychedelic treatments remains unlikely, but the tide is slowly turning. In 2019, FDA approved Spravato (esketamine) nasal spray for treatment of depression in adults. [8] Clinical Trials and Human Subject Protections. For the regulated community, this is a trend worth watching.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

NOVEMBER 24, 2019

Finding more information and committee details. Severe treatment-resistant epilepsy. People have the right to be involved in discussions and make informed decisions about their care, as described in your care. Do not offer CBD to manage chronic pain in adults unless as part of a clinical trial. Recommendations.

Medicine 59

Medicine Chronic Pain Research and Development Treatment 59

The Blunt Truth

AUGUST 13, 2019

On May 31, 2019, the FDA’s Working Group held a public hearing for stakeholders to share their experiences and challenges with CBD products, including information and views related to product safety. The Working Group is in the process of reviewing published medical literature and other available information from industry sponsors.

CBD 80

CBD Food Seed-To-Sale Wellness and Beauty 80

Cannabis Law Report

NOVEMBER 9, 2021

As an institution dedicated to diagnosing and treating serious blood diseases and with the ability to pursue investigational medicines from development to manufacture and clinical trial for patients who have exhausted all approved treatment options, having a cost-effective and rapid production chain is integral to ÚHKT’s mission.

Clinical Trials 52

Clinical Trials Research and Development Therapy Supply Chain 52

Cannabis Law Report

JANUARY 13, 2020

In particular, we see significant market opportunity for nabiximols in several indications in the US and will be progressing multiple late stage clinical programs in 2020.”. Commence clinical program in PTSD. Additional pipeline: Commence Phase 2b study of a cannabidiol formulation for the treatment of schizophrenia.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66